The significance of genetic drugs in the therapy of a new coronavirus infection and rheumatoid arthritis

Cytokines are mediators of intercellular correlations during inflammation and the formation of an immune response. Genetically engineered biological products (GEBPs) are a group of medicines that includes monoclonal antibody preparations. The effect of GEBPs is directed against pro-inflammatory cytokines (when the synthesis of the latter is significantly increased), their receptors and signaling pathways, helps to eliminate the imbalance of cytokines, that develops in such diseases as a new coronavirus infection and rheumatoid arthritis. The groups of GEBPs administered to patients with the new coronavirus infection and rheumatoid arthritis (RA) were analyzed. We studied 50 case histories of patients diagnosed with the new coronavirus infection (Group 1) and 64 patients diagnosed with RA (Group 2). In the treatment of coronavirus infection in patients with moderate and severe cases, drugs of 3 groups (inhibitors of IL-6 receptors; IL-6 inhibitors, as well as group A vascular endothelial growth factor inhibitors) are used. In the treatment of RA, TNF-α inhibitors, anti-B-cell drugs, inhibitors of T-cell activation are used in addition to drugs from the group of interleukin 6 inhibitors. The introduction of GEBPs makes it possible to achieve an improvement in clinical and laboratory parameters both with the new coronavirus infection and rheumatoid arthritis.

1. Lapotnikov V. A., Petrov V. N. Revmatoidnyj artrit [Rheumatoid arthritis]. Meditsinskaya sestra — Nurse, 2015, no. 7, pp. 24–25.

2. Zborovskaya I.A., Khanov A.G., Kapustina E.A. Uchebnik prakticheskoy revmatologii: rukovodstvo dlya vrachey [Textbook of practical rheumatology: A guide for physicians]. Rostov-on-Don, 2016. 376 p.

3. Shumpei Y., Yoshiyuki K., Kusuki N. Novaya koronavirusnaya bolezn' (COVID-19) i «tsitokinovyy shtorm». Perspektivy effektivnogo lecheniya s tochki zreniya patofiziologii vospalitel'nogo protsessa [New coronavirus disease (COVID-19) and cytokine storm. Prospects for effective treatment from the point of view of the pathophysiology of the inflammatory process]. Infektsionnyye bolezni: Novosti. Mneniya. Obucheniye — Infectious Diseases: News, Views, Education, 2020, vol. 9, no. 4(35), рр. 13–25. doi: https://doi.org/10.33029/23053496-2020-9-4-13-25

4. Kostiuk S.A., Simirsky V.V., Gorbich Y.L., et al. Tsitokinovyy shtorm pri COVID-19 [Cytokine storm at COVID19]. Mezhdunarodnyye obzory: klinicheskaya praktika i zdorov’ye — International Reviews: Clinical Practice and Health, 2021, no. 1, pp. 41–52.

5. Nasonov E.L., Karateev D.E., Chichasova N.V. Rekomendacii EULAR po lecheniyu revmatoidnogo artrita— 2013: obshchaya harakteristika i diskussionnye problemy [EULAR Recommendations for the Treatment of Rheumatoid Arthritis 2013: General characteristics and discussion problems]. Nauchno-prakticheskaya revmatologiya — Scientific and Practical Rheumatology, 2013, vol. 51, no. 6, pp. 609–622.

6. Namazova-Baranova L.S., Murashkin N.N., Ivanov R.A. Biologicheskaya terapiya v eru COVID-19 [Biological Therapy During COVID-19]. Voprosy sovremennoj pediatrii — Current Pediatrics, 2020, vol. 19, no. 2, pp. 116–122. doi: https://doi.org/10.15690/vsp.v19i2.2104

7. Vremennye metodicheskie rekomendacii «Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19)» Versiya 14 (27.12.2021) [Prevention, diagnosis and treatment of the new coronavirus infection (COVID-19). Temporary guidelines (version 14 of 27.12.2021)]. Moscow, Ministerstvo zdravoohraneniya Rossijskoj Federacii [Ministry of Health of the Russian Federation], 2021. 232 p. (In Russ.)

8. Nasonov E.L. Farmakoterapiya revmatoidnogo artrita: rossijskie i mezhdunarodnye rekomendacii [Pharmacotherapy for rheumatoid arthritis: Russian and international guidelines]. Nauchno-prakticheskaya revmatologiya — Scientific and Practical Rheumatology, 2016, no. 54(5), pp. 557–571. doi: https://doi.org/10.14412/1995-4484-2016-557-571

9. Mazurov V.I., Belyayeva I.B., Trofimov Ye.A., et al. Place of Mesto genno-inzhenernykh biologicheskikh i targetnykh preparatov v terapii revmatoidnogo artrita [Place of genetically engineered biological and targeted drugs in the treatment of rheumatoid arthritis]. Effektivnaya farmakoterapiya — Effective Pharmacotherapy, 2019, vol. 15, no. 40, pp. 36–44. doi: https://doi.org/10.33978/23073586-2019-15-40-36-44